By Vin Gurrieri ( October 19, 2015, 7:43 PM EDT) -- Biogen told the Patent Trial and Appeal Board on Friday to reject a bid by an organization with ties to hedge fund manager Kyle Bass to again consider instituting an America Invents Act review of a patent covering multiple sclerosis drug Tecfidera, saying the organization can't point to any error in the board's initial refusal....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.